Cargando…
Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT
Immune checkpoint inhibitors are currently the standard of care for many advanced solid tumors, and they have been recently approved for the treatment of relapsed/refractory Hodgkin lymphoma and primary mediastinal B cell lymphoma. Assessments of the response to immunotherapy may be complicated by t...
Autores principales: | Tutino, Francesca, Giovannini, Elisabetta, Chiola, Silvia, Giovacchini, Giampiero, Ciarmiello, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219254/ https://www.ncbi.nlm.nih.gov/pubmed/37240602 http://dx.doi.org/10.3390/jcm12103498 |
Ejemplares similares
-
Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications
por: Pastorino, Sara, et al.
Publicado: (2020) -
Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
por: Al-Ibraheem, Akram, et al.
Publicado: (2022) -
The role of FDG-PET in Hodgkin lymphoma
por: Subocz, Edyta, et al.
Publicado: (2017) -
Occipital Hypometabolism on FDG PET/CT Scan in a Child with Hodgkin's Lymphoma
por: Uslu Biner, Inci, et al.
Publicado: (2016) -
[(18)F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives
por: Kanoun, Salim, et al.
Publicado: (2018)